| atomoxetine / Generic mfg. |
| Completed | 3b | 153 | RoW | Atomoxetine Hydrochloride, LY139603, Strattera, Atomoxetine hydrochloride | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 11/08 | 11/08 | | |
NCT01106430 / 2009-011745-94: Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate |
|
|
| Completed | 3b | 267 | Europe, Canada, US | Lisdexamfetamine Dimesylate, Vyvanse, Atomoxetine Hydrochloride, Strattera | Shire | Attention-Deficit/Hyperactivity Disorder | 07/12 | 07/12 | | |
ACTRN12624000342516: A trial of the effectiveness of tablet medication to prevent low blood pressure after surgery |
|
|
| Not yet recruiting | 3 | 90 | | | The Royal Melbourne Hospital, The Australian and New Zealand College of Anaesthetists | Postoperative hypotension | | | | |
NCT00486083: Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD |
|
|
| Completed | 3 | 330 | RoW | Atomoxetine Hydrochloride, Methylphenidate Hydrochloride | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 10/04 | | |
NCT00557960: ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD |
|
|
| Completed | 3 | 36 | US | Mixed salts of a single-entity amphetamine, ADDERALL XR, Atomoxetine hydrochloride, STRATTERA | Shire | Attention Deficit Disorder With Hyperactivity | 10/04 | 10/04 | | |
NCT00485459: Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD |
|
|
| Completed | 3 | 106 | RoW | Atomoxetine Hydrochloride, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 11/04 | | |
NCT00386581: Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 105 | RoW | atomoxetine, placebo | Eli Lilly and Company | Attention Deficit Disorder With Hyperactivity | | 02/05 | | |
NCT00485550: Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy |
|
|
| Completed | 3 | 14 | US | Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 03/05 | | |
NCT00485407: Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine |
|
|
| Completed | 3 | 377 | US, Canada | Atomoxetine Hydrochloride | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 06/05 | | |
NCT00191698: Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD |
|
|
| Completed | 3 | 226 | Europe, RoW | atomoxetine hydrochloride, LY139603, Strattera, placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | 06/05 | 11/07 | | |
NCT00191737: An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 147 | Europe | Atomoxetine | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 02/06 | | |
NCT00191516: An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 257 | Europe | Atomoxetine | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 02/06 | | |
NCT00191659: Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents |
|
|
| Completed | 3 | 200 | Europe | Atomoxetine Hydrochloride | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 04/06 | | |
NCT00191880: Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 100 | Canada | atomoxetine | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 06/06 | | |
NCT00192023: An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). |
|
|
| Completed | 3 | 139 | Europe | atomoxetine 0.5 mg/kg/day, LY139603, Strattera, placebo, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | 08/06 | 05/08 | | |
| Completed | 3 | 100 | Europe | Atomoxetine, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 08/06 | | |
NCT00216281: Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia |
|
|
| Terminated | 3 | 126 | US | Clozapine augmented with atomoxetine up to 40 mg or placebo | Indiana University School of Medicine, Hoffmann-La Roche, Shekhar, Anantha M.D., Ph.D. | Schizophrenia | 10/06 | 09/08 | | |
NCT00191945 / 2004-004088-31: Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 151 | Europe | Atomoxetine Hydrochloride, LY139603, Strattera, placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 02/08 | 02/08 | | |
NCT00320528 / 2005-005701-32: Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 269 | Europe | atomoxetine, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Disorder With Hyperactivity | 10/08 | 10/08 | | |
ADHD LIFE, NCT00447278 / 2006-005512-27: A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents |
|
|
| Completed | 3 | 399 | Europe, RoW | Atomoxetine, LY139603, Strattera, Other standard therapy for ADHD | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 03/09 | 07/09 | | |
| Completed | 3 | 228 | Japan | Atomoxetine hydrochloride, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 08/09 | 08/09 | | |
| Completed | 3 | 1553 | US, Canada, Europe, RoW | atomoxetine, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 10/09 | 10/09 | | |
NCT00962104: Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 391 | Japan, RoW | Atomoxetine, LY139603, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 02/11 | 02/11 | | |
| Completed | 3 | 2017 | Europe | atomoxetine hydrochloride, Strattera, LY139603, atomoxetine, Placebo | Eli Lilly and Company, , Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 08/11 | 10/13 | | |
NCT00969618: A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 211 | Japan | Atomoxetine, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 01/12 | 01/12 | | |
NCT01244490 / 2010-018579-12: Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 338 | Europe, Canada, US, RoW | Extended-release Guanfacine Hydrochloride, Intuniv, Atomoxetine Hydrochloride, Strattera, Placebo Comparator | Shire | Attention Deficit Hyperactivity Disorder | 05/13 | 05/13 | | |
2007-007672-41: A study in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) who are not hospitalized in which the study first gives the patient a pill containing Atomoxetine Hydrochloride. Later in the study the patients are split into two groups with one group receiving Atomoxetine Hydrochloride in a pill and the other placebo (a pill that has a similar appearance to Atomoxetine Hydrochloride but has no medicine). |
|
|
| Completed | 3 | 2000 | Europe | Atomoxetine hydrochloride, LY139603, Capsule, hard, Strattera | Eli Lilly and Company, Lilly S.A., Eli Lilly and Company Limitated, , Eli Lilly and Company | Attention-Deficit/Hyperactivity Disorder (ADHD), A condition making it difficult to control your behavior, activity level and attention level., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 3 | 10 | US | ATM FOG in PD | Medical University of South Carolina | Parkinson's Disease, Freezing of Gait | 02/14 | 02/14 | | |
B4Z-US-050, NCT00418262: Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD |
|
|
| Completed | 3 | 27 | US | Atomoxetine, Brand Name: Strattera, Serial Number: 76306506, ACT | University of Oklahoma, Mark L. Wolraich | Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD) | 04/15 | 04/15 | | |
NCT00498173: Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism |
|
|
| Completed | 3 | 60 | US | Atomoxetine, Strattera, Placebo | Massachusetts General Hospital, National Institute of Mental Health (NIMH) | Autism | 10/15 | 10/15 | | |
NCT01330693: Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy |
|
|
| Unknown status | 3 | 120 | US | Atomoxetine, Strattera, Sugar Pill | University of Cincinnati, National Institute of Mental Health (NIMH) | Attention Deficit Disorder With Hyperactivity | 11/15 | 11/15 | | |
NCT00255138: Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects |
|
|
| Withdrawn | 3 | 0 | US | Atomoxetine | Temple University, Eli Lilly and Company | Cancer, Cognitive Late Effects | | | | |
| Recruiting | 3 | 180 | Canada | Atomoxetine Hydrochloride, Placebo | University of Calgary | Vasovagal Syncope | 09/26 | 09/27 | | |
| Recruiting | 3 | 40 | RoW | Atomoxetine, atomox, Coenzyme Q | Sherief Abd-Elsalam | ADHD | 12/30 | 12/30 | | |
NCT00191009: Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease |
|
|
| Completed | 2/3 | 124 | US | atomoxetine hydrochloride, placebo | Eli Lilly and Company | Alzheimer Disease | | 01/06 | | |
NCT00191295: Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2/3 | 240 | Japan | Atomoxetine, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 09/06 | | |
NCT00260533: Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder |
|
|
| Completed | 2/3 | 27 | US | atomoxetine, Strattera, placebo | University of California, San Diego, Eli Lilly and Company | Generalized Social Phobia | 07/08 | 07/08 | | |
